Find Clinical Trial

A Phase 2 Clinical Study of Pegaspargase in Patients With Newly Diagnosed, Untreated Acute Lymphoblastic Leukemia


← Back
Study Phase

Phase 2

Therapeutic Area

Cancers

Active substance/
Medical device

PEGASPARGASE,
S095014

SponsorInstitut de Recherches Internationales Servier
Active Substance CodeS095014
Protocol CodeCL1-95014-001
NCT CodeNCT04067518


Documents and links

Results are not yet available.




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2017 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
More information

Report a side-effect with a drug.
Accessibility